|
HIV-1 infection
|
|
0.030 |
GeneticVariation
|
BEFREE |
Structural insight into a novel human CCR5-V130I variant associated with resistance to HIV-1 infection.
|
23869485 |
2014 |
|
HIV-1 infection
|
|
0.030 |
GeneticVariation
|
BEFREE |
In addition, we also identified the best three-factor interaction model, including the CCR5 58755-A/G, 59029-A/G, and CCR2-V64I polymorphisms, indicating that there were also strong gene-gene interactions between the CCR5 promoter and CCR2 polymorphisms on the susceptibility of HIV-1 infection.
|
23057571 |
2012 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
|
0.030 |
GeneticVariation
|
BEFREE |
In a North American, treated, adherent human immunodeficiency virus (HIV)-positive cohort (self-identified whites, n = 175; blacks, n = 218), we investigated whether CYP2B6 (516G>T, 983T>C), UGT2B7 (IVS1+985A>G, 802C>T), MDR1 3435C>T, chemokine (C-C motif) receptor 2 (CCR2) 190G>A, and CCR5 (-2459G>A, Δ32) polymorphisms influenced the time to achieve virologic success (TVLS).
|
21673041 |
2011 |
|
HIV-1 infection
|
|
0.030 |
GeneticVariation
|
BEFREE |
A single nucleotide polymorphism (SNP) at codon 64 in the CC chemokine receptor 2 gene (CCR2 V64I) has been associated with a dominant effect of delaying disease progression from human immunodeficiency virus-1 (HIV-1) infection to acquired immunodeficiency syndrome (AIDS).
|
12325020 |
2002 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
|
0.030 |
GeneticVariation
|
BEFREE |
A single nucleotide polymorphism (SNP) at codon 64 in the CC chemokine receptor 2 gene (CCR2 V64I) has been associated with a dominant effect of delaying disease progression from human immunodeficiency virus-1 (HIV-1) infection to acquired immunodeficiency syndrome (AIDS).
|
12325020 |
2002 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
|
0.030 |
GeneticVariation
|
BEFREE |
Of the 99 HIV-seronegative female workers, 19 (19.2%) were heterozygous for the CCR2b-V64I mutation compared with 37 (23%) of the 161 HIV-seropositive FSW (P = 0.47).
|
11468722 |
2001 |
|
Parkinson Disease
|
|
0.020 |
GeneticVariation
|
BEFREE |
However, CCR2 V64I polymorphism is not correlated with PD risk.
|
31471711 |
2019 |
|
Neoplasm Metastasis
|
|
0.020 |
GeneticVariation
|
BEFREE |
No significant associations were found in relation to susceptibility (CCR2-V64I: OR 1.32; 95 % CI 0.57-3.06; CCR5-∆32: OR 1.04; 95 % CI 0.60-1.81), clinical outcome (tumor size, lymph nodes commitment and/or distant metastasis, TNM staging and nuclear grade) or therapeutic response (recurrence and survival).
|
25716470 |
2016 |
|
Malignant neoplasm of prostate
|
|
0.020 |
GeneticVariation
|
BEFREE |
However, -2518 (A > G) and CCR2 V64I (G > A) gene polymorphisms were not significantly associated with PCa risk.
|
25266801 |
2015 |
|
Parkinson Disease
|
|
0.020 |
GeneticVariation
|
BEFREE |
In this study, a cohort of 521 PD patients and 556 cases of healthy controls were recruited to investigate the association between the MCP-1 2518A/G (rs1064211) and CCR2 V64I (rs1799864) gene polymorphisms and PD risk in the Chinese population.
|
25370917 |
2015 |
|
Prostate carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
However, -2518 (A > G) and CCR2 V64I (G > A) gene polymorphisms were not significantly associated with PCa risk.
|
25266801 |
2015 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
When the data were stratified by study location, the increased risk of cancer among A allele carriers of CCR2 V64I was observed only in studies conducted in Asian countries (AA+AG vs. GG: OR=1.65; 95% CI=1.25-2.18).
|
23876399 |
2013 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
These data suggested that MCP-1 -2518A/G and CCR2 190G/A polymorphisms are new risk factors for RCC and could be used as prognostic markers for this malignancy.
|
23657965 |
2013 |
|
Malignant Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
When the data were stratified by study location, the increased risk of cancer among A allele carriers of CCR2 V64I was observed only in studies conducted in Asian countries (AA+AG vs. GG: OR=1.65; 95% CI=1.25-2.18).
|
23876399 |
2013 |
|
Malignant Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
These data suggested that MCP-1 -2518A/G and CCR2 190G/A polymorphisms are new risk factors for RCC and could be used as prognostic markers for this malignancy.
|
23657965 |
2013 |
|
Malignant neoplasm of prostate
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our data indicate that gene polymorphism of CCR2 V64I may influence the susceptibility and clinicopathological characteristics of prostate cancer and CCR5 Δ32 allele may also be an important risk factor for prostate cancer in Turkish men population.
|
22612293 |
2012 |
|
Prostate carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our data indicate that gene polymorphism of CCR2 V64I may influence the susceptibility and clinicopathological characteristics of prostate cancer and CCR5 Δ32 allele may also be an important risk factor for prostate cancer in Turkish men population.
|
22612293 |
2012 |
|
Bladder Neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
Additionally, the combination of CCR2 V64I and CCR5 Δ32 (i.e., GG-wt/Δ32) was found to be associated with BC risk.
|
22982413 |
2012 |
|
Malignant neoplasm of urinary bladder
|
|
0.020 |
GeneticVariation
|
BEFREE |
Additionally, the combination of CCR2 V64I and CCR5 Δ32 (i.e., GG-wt/Δ32) was found to be associated with BC risk.
|
22982413 |
2012 |
|
Neoplasm Metastasis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Prostate cancer patients carrying AA genotype or at least one A allele of CCR2 V64I had significantly increased risk for high stage disease (p=0.002 and p=0.039, respectively) and metastasis (p=0.004 and p=0.022, respectively).
|
22612293 |
2012 |
|
Carcinoma of bladder
|
|
0.020 |
GeneticVariation
|
BEFREE |
Additionally, the combination of CCR2 V64I and CCR5 Δ32 (i.e., GG-wt/Δ32) was found to be associated with BC risk.
|
22982413 |
2012 |
|
Carcinoma of bladder
|
|
0.020 |
GeneticVariation
|
BEFREE |
Individuals carrying the CCR2-V64I heterozygote or homozygous variant genotype (64I/64I + wt/64I) had a 2.9-fold increased risk of bladder cancer compared with the wild-type genotype (wt/wt).
|
20449800 |
2010 |
|
Malignant neoplasm of urinary bladder
|
|
0.020 |
GeneticVariation
|
BEFREE |
Individuals carrying the CCR2-V64I heterozygote or homozygous variant genotype (64I/64I + wt/64I) had a 2.9-fold increased risk of bladder cancer compared with the wild-type genotype (wt/wt).
|
20449800 |
2010 |
|
Bladder Neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
Individuals carrying the CCR2-V64I heterozygote or homozygous variant genotype (64I/64I + wt/64I) had a 2.9-fold increased risk of bladder cancer compared with the wild-type genotype (wt/wt).
|
20449800 |
2010 |
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
No significant associations were found in relation to susceptibility (CCR2-V64I: OR 1.32; 95 % CI 0.57-3.06; CCR5-∆32: OR 1.04; 95 % CI 0.60-1.81), clinical outcome (tumor size, lymph nodes commitment and/or distant metastasis, TNM staging and nuclear grade) or therapeutic response (recurrence and survival).
|
25716470 |
2016 |